(Total Views: 307)
Posted On: 04/14/2022 10:45:53 AM
Post# of 61

$GALT News Article - Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis https://marketwirenews.com/news-releases/gale...35999.html


My Twitter: WhyteStocks